- Home
- RZLV vs KOD Comparison
RZLV vs KOD Comparison
Compare RZLV & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLV
- KOD
- Stock Information
- Founded
- RZLV 2016
- KOD 2009
- Country
- RZLV United Kingdom
- KOD United States
- Employees
- RZLV N/A
- KOD N/A
- Industry
- RZLV
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RZLV
- KOD Health Care
- Exchange
- RZLV NYSE
- KOD Nasdaq
- Market Cap
- RZLV 526.2M
- KOD 454.7M
- IPO Year
- RZLV N/A
- KOD 2018
- Fundamental
- Price
- RZLV $2.86
- KOD $7.50
- Analyst Decision
- RZLV Strong Buy
- KOD Hold
- Analyst Count
- RZLV 4
- KOD 4
- Target Price
- RZLV $5.50
- KOD $8.00
- AVG Volume (30 Days)
- RZLV 15.0M
- KOD 448.1K
- Earning Date
- RZLV 02-21-2025
- KOD 11-14-2024
- Dividend Yield
- RZLV N/A
- KOD N/A
- EPS Growth
- RZLV N/A
- KOD N/A
- EPS
- RZLV N/A
- KOD N/A
- Revenue
- RZLV $145,051.00
- KOD N/A
- Revenue This Year
- RZLV $244.80
- KOD N/A
- Revenue Next Year
- RZLV $9,101.29
- KOD N/A
- P/E Ratio
- RZLV N/A
- KOD N/A
- Revenue Growth
- RZLV 25.96
- KOD N/A
- 52 Week Low
- RZLV $1.57
- KOD $2.19
- 52 Week High
- RZLV $14.50
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- RZLV N/A
- KOD 44.49
- Support Level
- RZLV N/A
- KOD $7.21
- Resistance Level
- RZLV N/A
- KOD $9.14
- Average True Range (ATR)
- RZLV 0.00
- KOD 0.86
- MACD
- RZLV 0.00
- KOD -0.33
- Stochastic Oscillator
- RZLV 0.00
- KOD 15.73
About RZLV REZOLVE AI LTD
Rezolve AI Ltd provides a mobile commerce and engagement platform, underpinned by machine learning, that enables retailers, brands and manufacturers to engage with consumers in a broad range of locations and settings via their mobile devices and personal computers. its platform allows for mobile engagement with merchants using its software to extend their business to consumers' mobile devices and computers in different ways.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.